

online from January 2009



ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

ISSN: 0250-7005

- ANTICANCER RESEARCH is an independent international forum devoted to the rapid publication of original high quality articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months from acceptance are guaranteed.

● Selection of Recent Articles

Differentially Regulated Genes in MEN1 Transfected BON Cells Using RT-differential Display, and Oligonucleotide Microarrays. J.R. LOPEZ-EGIDO, Y. WANG, M. GRÖNBERG, P. GRIMFJÄRD, S. WANG, P. STÅLBERG, B. SKOGSEID (*Uppsala, Sweden*)

Bortezomib Therapeutic Effect Is Associated with Expression of FGFR3 in Multiple Myeloma Cells. M. GUAN, L. ZHU, G. SOMLO, A. HUGHES, B. ZHOU, Y. YEN (*Duarte, CA, USA; Zhejiang, China*)

Utilization of a Right-handed Coiled-coil Protein from Archaeobacteria *Staphylothermus marinus* as a Carrier for Cisplatin. M. ERIKSSON, S. HASSAN, R. LARSSON, S. LINDER, T. RAMQVIST, H. LÖVBORG, T. VIKINGE, E. FIGGEMEIER, J. MÜLLER, J. STETEFELD, T. DALIANIS, S. ÖZBEK (*Stockholm; Uppsala; Linköping, Sweden; Basel, Switzerland; Winnipeg, Manitoba, Canada; Heidelberg, Germany*)

An Orally Active Small Molecule TGF- β Receptor I Antagonist Inhibits the Growth of Metastatic Murine Breast Cancer. M.P. RAUSCH, T. HAHN, L. RAMANATHAPURAM, D. BRADLEY-DUNLOP, D. MAHADEVAN, M.E. MERCADO-PIMENTEL, R.B. RUNYAN, D.G. BESSELSSEN, X. ZHANG, H.-K. CHEUNG, W.-C. LEE, L.E. LING, E.T. AKPORIAYE (*Tucson, AZ; Portland, OR; Cambridge, MA, USA*)

Overexpression of Adenovirus-mediated p27kip1 Lacking the Jab1-Binding Region Enhanced Cytotoxicity and Inhibited Xenografted Human Cholangiocarcinoma Growth. S. SHIRASO, Y. KATAYOSE, K. YAMAMOTO, M. MIZUMA, S. YABUUCHI, A. ODA, T. RIKIYAMA, T. ONOGAWA, H. YOSHIDA, H. HAYASHI, H. OHTSUKA, F. MOTOI, S. EGAWA, J. KATO, M. UNNO (*Sendai; Nara, Japan*)

Analysis of Factors Influencing Dysphagia Severity Following Treatment of Head and Neck Cancer. N.P. NGUYEN, C. FRANK, C.C. MOLTZ, U. KARLSSON, P.D. NGUYEN, H.W.C. WARD, P. VOS, H.J. SMITH, S. HUANG, L.M. NGUYEN, C. LEMANSKI, A. LUDIN, S. SALLAH (*Tucson, AZ; Dallas, TX; Greenville, NC; Ann Arbor, MI; Cleveland, OH, USA; Montpellier, France; Athens, Greece*)

The Hedgehog Signaling Pathway Plays an Essential Role in Maintaining the CD44+CD24-/low Subpopulation and the Side Population of Breast Cancer Cells. H. TANAKA, M. NAKAMURA, C. KAMEDA, M. KUBO, N. SATO, S. KUROKI, M. TANAKA, M. KATANNO (*Fukuoka, Japan*)

A Role for the Substance P/NK-1 Receptor Complex in Cell proliferation in Oral Squamous Cell Carcinoma. S. BRENER, M.A. GONZÁLEZ-MOLE, D. TOSTES, F. ESTABAN, J.A. GIL-MONTOYA, I. RUIZ-ÁVILA, M. BRAVO, M. MUÑOZ (*Sao Paulo, Brazil; Granada; Sevilla; Jaen, Spain*)

Comparison of Cell Death-inducing Effect of Novel Taxane SB-T-1216 and Paclitaxel in Breast Cancer Cells. J. KOVÁ, M. EHRLIHOVÁ, B. ŠMEJKALOVÁ, I. ZANARDI, I. OJIMA (*Prague, Czech Republic; Stony Brook, NY, USA*)

Conversion from Calcineurin Inhibitors to Sirolimus Reduces Vascularization and Thickness of Post-transplant Cutaneous Squamous-cell Carcinomas. A.-L. RIVAL-TRINGALI, S. EUVRARD, E. DECULLIER, A. CLAUDY, M. FAURE, J. KANITAKIS (*Lyon, France*)

Vessel Dilator and Kaliuretic Peptide Inhibit Ras in Human Prostate Cancer Cells. Y. SUN, E.J. EICHELBAUM, W.P. SKELTON IV, A. LENZ, H. WANG, D.L. VESELY (*Tampa, FL, USA*)

Pharmacological Interplay between Breast Cancer Resistance Protein and Gefitinib in Epidermal Growth Factor Receptor Signaling. K. KATAYAMA, K. SHIBATA, J. MITSUHASHI, K. NOGUCHI, Y. SUGIMOTO (*Tokyo, Japan*)

Levonorgestrel, Medroxyprogesterone and Progesterone Cause a Concentration-dependent Reduction in Endometrial Cancer (Ishikawa) Cell Density, and High Concentrations of Progesterone and Mifepristone Act in Synergy. B.T. MOE, A.B. VEREIDE, A. ØRBO, R. JÆGER, G. SAGER (*Tromsø, Norway*)


- **Editorial Office:** Manuscripts and correspondence should be addressed to: Dr. John G. Delinassios, Managing Editor, Anticancer Research, Editorial Office, International Institute of Anticancer Research (IIAR), 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece.
Tel & Fax: +30-22950-53389, e-mail: journals@iiar-anticancer.org

- For more information about Anticancer Research and IIAR, please visit the IIAR website: www.iiar-anticancer.org

FREE SPECIMEN COPIES OF ANTICANCER RESEARCH ARE AVAILABLE ON REQUEST

CANCER GENOMICS & PROTEOMICS

online from January 2009



www.cgp-journal.com

Print ISSN: 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004) - VOL. 2 (2005) - VOL. 3 (2006)

VOL. 4 (2007) - VOL. 5 (2008) - VOL. 6 (2009)

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 2-4 months from submission or 1-2 months from acceptance.

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PUBMED, ^aDLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE, Compendex, GEOBASE, EMBiology, FLUIDEX, Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal, PubsHub, SIIC.

Editorial Office: International Institute of Anticancer Research

1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece.

Tel: +30 22950 52945, Fax: +30 22950 53389

e-mail: journals@iiar-anticancer.org (Editorial Office); editor@iiar-anticancer.org, editor@cgp-journal.com (Managing Editor)

A Selection of Recent Papers

Secondary Structure at a Hot Spot for DNA Methylation in DNA from Human Breast Cancers. J. CLARK, S.S. SMITH (*Duarte, CA, USA*)

Molecular Mechanisms of Action of Imatinib Mesylate in Human Ovarian Cancer: A Proteomic Analysis. B.B. PATEL, Y.A. HE, X.-M. LI, A. FROLOV, L. VANDERVEER, C. SLATER, R.J. SCHILDER, M. VON MEHREN, A.K. GODWIN, A.T. YEUNG (*Philadelphia, PA; Birmingham, AL, USA*)

Tissue Microarrays of Human Tumor Xenografts: Characterization of Proteins Involved in Migration and Angiogenesis for Applications in the Development of Targeted Anticancer Agents. V. SMITH, G.J. WIRTH, H.-H. FIEBIG, A.M. BURGER (*Freiburg, Germany; Geneva, Switzerland; Detroit, MI, USA*)

Ochratoxin A Lowers mRNA Levels of Genes Encoding for Key Proteins of Liver Metabolism. C. HUNDHAUSEN, C. BOESCH-SAADATMANDI, N. MATZNER, F. LANG, R. BLANK, S. WOLFFRAM, W. BLASCHEK, G. RIMBACH (*Kiel; Tuebingen, Germany*)

Immune Response Signatures of Benzo(α)pyrene Exposure in Normal Human Mammary Epithelial Cells in the Absence or Presence of Chlorophyllin. K. JOHN, C. KESHAVA, D.L. RICHARDSON, A. WESTON, J. NATH (*Morgantown, WV, USA*)

The Protein Expression of TRP-1 and Galectin-1 in Cutaneous Malignant Melanomas. Å. BOLANDER, M. AGNARSDÓTTIR, S. STRÖMBERG, F. PONTEN, P. HESSELIUS, M. UHLEN, M. BERGQVIST (*Uppsala; Stockholm, Sweden*)

Phenotypic Subpopulations of Metastatic Colon Cancer Stem Cells: Genomic Analysis. I.L. BOTCHKINA, R.A. ROWEHL, D.E. RIVADENEIRA, M.S. KARPEH Jr., HOWARD CRAWFORD, A. DUFOUR, J. JU, Y. WANG, Y. LEYFMAN, G.I. BOTCHKINA (*San Francisco, CA; Stony Brook, New York, NY, USA*)

Relative Quantification of Cytochrome P450 1B1 Gene Expression in Peripheral Leukocytes using LightCycler. S. HELMIG, B. HADZAAD, J. DÖHREL, J. SCHNEIDER (*Giessen, Germany*)

Label-free Global Serum Proteomic Profiling Reveals Novel Celecoxib-modulated Proteins in Familial Adenomatous Polyposis Patients. N. FATIMA, D. CHELIUS, B.T. LUKE, M. YI, T. ZHANG, S. STAUFFER, R. STEPHENS, P. LYNCH, K. MILLER, T. GUSZCZYNSKI, D. BORING, P. GREENWALD, I.U. ALI (*Bethesda; Frederick, MD; San Jose, CA; Houston, TX, USA*)

A Gene Expression Profiling Approach Assessing Celecoxib in a Randomized Controlled Trial in Poststate Cancer. P. SOORIAKUMARAN, P. MACANAS-PIRARD, G. BUCCA, A. HENDERSON, S.E.M. LANGLEY, R.W. LAING, C.P. SMITH, E.E. LAING, H.M. COLEY (*Surrey, UK*)

Reduced expression of BMPR-IB correlates with poor prognosis and increased proliferation of breast cancer cells. S.M. BOKOBZA, L. YE, H.E. KYNASTON, R.E. MANSEL, W.G. JIANG (*Cardiff, UK*)

Down-regulation of Microfilament Network-Associated Proteins in Leukocytes of Breast Cancer Patients: Potential Application to Predictive Diagnostics. M. BRAUN, M. FOUNTOULAKIS, A. PAPAPOULOU, K. VOUGAS, I. SEIDEL, T. HÖLLER, K. YEGHIAZARYAN, H.H. SCHILD, W. KUHN, O. GOLUBNITSCHAJA (*Bonn, Germany; Athens, Greece*)

Genomic Analysis of Prostate Cancer Stem Cells Isolated from a Highly Metastatic Cell Line. R.A. ROWEHL, H. CRAWFORD, A. DUFOUR, J. JU, G.I. BOTCHKINA (*Stony Brook, NY, USA*)

Subscription Order Form 2009

- Please enter a Subscription to IN VIVO for Volume 23 (2009).
Annual subscription rates (2009): Institutional, Euro 855.00 - online; Euro 875.00 - print; 890.00 - print & online; Personal, Euro 452.00 - online; Euro 472.00 - print; Euro 490.00 - print & online. Prices include rapid delivery and insurance.
- Please send me the following previous volumes (1-22) at 50% discount on the above rates.
- Payment is enclosed. Please invoice.
(Cheques should be made payable to J.G. Delinassios, Athens, Greece)
- Please send me information about the International Institute of Anticancer Research (IIAR).

Name and Address:

Tel:

Fax: e-mail:

Signature: Date:

Please send this order to IN VIVO, Editorial Office, IIAR, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece. Tel & Fax: +30-22950-53389, e-mail: journals@iiar-anticancer.org

Special 2009 Offers to Authors of IN VIVO

(These offers are open to all authors of articles published in IN VIVO 1987-2009 on a basis of priority and availability. Effective from January to December 2009).



- 1987-2008
- 22 volumes
- over 14,400 pages
- over 2,290 original articles and reviews
- over 9,100 authors
- Special issues
- Conference abstracts
- Author-Subject Indexes

Please complete and send this order form to:
ANTICANCER RESEARCH Editorial Office, International Institute of Anticancer Research,
1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece.

Special Subscription Order Form 2009

- I am one of the authors of the article published in IN VIVO Vol....., pp., year
- Please enter my personal subscription to IN VIVO 2009 (Volume 23) at the special Author's rate of Euro 216.00 (print or online); Euro 300.00 (print & online).
- Please send me previous Volume No(s) at Euro 108.00 per volume.
- Please enter my personal combined 2009 subscription to IN VIVO (Volume 23), ANTICANCER RESEARCH (Volume 29) and CANCER GENOMICS & PROTEOMICS at Euro 755.00 (print or online); Euro 972,00 (print & online).
- My payment is enclosed.
- Please send me an invoice.
(Prices include rapid delivery and insurance. Cheques should be made payable to J.G. Delinassios, Athens, Greece).

Name and address:

Tel-Fax:

e-mail:

Date and signature:

Instructions to Authors

General Policy. IN VIVO is a multidisciplinary journal designed to bring together high quality original works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The focus of the journal is the publication of works on: (a) experimental development and application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; and (c) development and characterization of models for biomedical research. A main aim of IN VIVO is to ensure the prompt publication of accepted articles, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report unpublished original works that are not under consideration for publication by another journal, and that they will not be published again in the same form. On publication of a manuscript in IN VIVO, which is a copyrighted publication, the legal ownership of all published parts of the manuscript passes from the Author(s) to the Journal. All material submitted to IN VIVO will be subject to review, when appropriate, by two members of the Editorial Board. The Editors reserve the right to improve manuscripts in terms of grammar and style. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. The *Guiding Principles in the Care and Use of Animals* approved by the Council of the American Physiological Society must be followed. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in IN VIVO for public archiving in PubMed Central.

Manuscripts. Two types of papers may be submitted: (i) papers containing completed original work, and (ii) review articles concerning fields of recognizable progress. Papers should be written in clear, concise English. Spelling should follow that of the "Oxford English Dictionary". Ideally, manuscripts should not exceed fourteen (14) pages (approx. 250 words per double-spaced page) corresponding to four (4) printed pages. Papers exceeding four (4) printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work, full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words and an abbreviated running title; (b) Abstract not exceeding 150 words, organized according to the following headings: Background - Materials and Methods or Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods or Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; and (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's preference. Review articles should not exceed 35 pages (approximately 250 words per double-spaced page) including all tables, figures and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, rather than photographic copies. A charge will be made for a colour plate. Figures should be numbered with Arabic numerals and include a short title, and legend if appropriate.

Tables. Each table should be submitted on a separate page, double-spaced. Tables should be numbered with Roman numerals and should include a short title and legend if appropriate.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined on first usage.

References. Citations for the reference section of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively in the order that they appear in the text. Examples : 1 Sumner AT : The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamness GC: Studies on the oestrogen receptor in breast cancer. *In: Receptors for Reproductive Hormones.* O' Malley BW and Chamness GC (eds.). New York, Plenum Publ Corp, pp. 113-136, 1973. In the text, references should be denoted as: (1), (2-5), (6, 7) etc.

Submission of Manuscripts. You can send your article via e-mail to journals@iiar-anticancer.org, indicating in which journal you wish to be submitted (ANTICANCER RESEARCH, IN VIVO or CANCER GENOMICS & PROTEOMICS). The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments. **OR** You can send the manuscript of your article via regular mail in a usb stick, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address: Dr. J.G. Delinassios, International Institute of Anticancer Research (IIAR), Editorial Office of ANTICANCER RESEARCH, IN VIVO and CANCER GENOMICS & PROTEOMICS. 1st km Kapandritiou-Kalamou Road, P.O. Box 22, GR-19014, Kapandriti, Attiki, Greece. Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent by e-mail to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Reprints may be ordered after the acceptance of the paper.

Cord Blood Survivin Concentrations in Human Full-term Normal and Complicated Pregnancies. A. MALAMITSI-PUCHNER, S. BAKA, M. BOUTSIKOU, S. LIOSI, D. GOURGIOTIS, E. PROTONOTARIOU, D. HASSIAKOS, D.D. BRIANA (<i>Athens, Greece</i>).....	139
* Current Role and Future Perspectives of Hyperthermia for Prostate Cancer Treatment. G. BARONZIO, A. GRAMAGLIA, G. FIORENTINI (<i>Monza; Empoli, Italy</i>).....	143
Evaluation of Quality of Life of Patients Submitted to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis of Gastrointestinal and Ovarian Origin and Identification of Factors Influencing Outcome. A. MACRÌ, I. MAUGERI, G. TRIMARCHI, R. CAMINITI, M.C. SAFFIOTI, S. INCARDONA, A. SINARDI, S. IRATO, G. ALTAVILLA, V. ADAMO, A. VERSACI, C. FAMULARI (<i>Messina, Italy</i>)	147
Colobronchial Fistula: An Unusual Complication after Peritonectomy and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC). B. LATERZA, D. BARATTI, G. COZZI, S. KUSAMURA, G.D. OLIVA, C. GAVAZZI, L. FUMAGALLI, A. SIRONI, D. SABIA, M. DERACO (<i>Milan, Italy</i>).....	151
Associations of Lipoprotein Lipase S447X and Apolipoprotein E Genotypes with Low-density Lipoprotein Subfractions in Turkish Patients with Coronary Artery Disease. H. YILMAZ AYDOGAN, S. ISBİR, O. KURNAZ, U. GORMUS, T. ISBİR (<i>Istanbul, Turkey</i>).....	155
Congenital Cholesteatoma Associated with Blue Eardrum. C.H. JANG, Y.-B. CHO, Y.H. KIM, P.-C. WANG (<i>Gwangju; Iksan, South Korea; Taipei, Taiwan, ROC</i>).....	163
A Primary Large Cholesterol Cyst of the Mastoid Presenting with Dysgeusia. C.-H. JANG, Y.H. KIM, Y.B. CHO (<i>Gwangju; Iksan, South Korea</i>).....	167
A Randomized Study of Chemotherapy Versus Biochemotherapy with Chemotherapy plus <i>Aloe arborescens</i> in Patients with Metastatic Cancer. P. LISSONI, F. ROVELLI, F. BRIVIO, R. ZAGO, M. COLCIAGO, G. MESSINA, A. MORA, G. PORRO (<i>Monza; Lecco, Italy</i>)	171
Platelet GP IIIA Polymorphism HPA-1 (PLA1/2) Is Associated with Hypertension as the Primary Cause for End-stage Renal Disease in Hemodialysis Patients from Greece. T. CHIRAS, E.D. PAPADAKIS, A. KATOPODI, E. CHATZIANESTI, K. FOURTOUNAS, S. PAPAKONSTANTINOY, I. THEODOROPOULOS, A. DAKOURAS, N. ZEREFOS, D. VALIS, H. TZANATOS-EXARCHOU (<i>Athens, Greece</i>)	177
Antibacterial Effect of Octylcyanoacrylate against Ciprofloxacin-resistant <i>Pseudomonas aeruginosa</i> Isolates from Patients with Chronic Suppurative Otitis Media. C.H. JANG, H. PARK, Y.B. CHO, C.H. CHOI, C. SONG (<i>Gwangju, South Korea</i>).....	183
Role of Explorative Laparoscopy to Evaluate Optimal Candidates for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients with Peritoneal Mesothelioma. B. LATERZA, S. KUSAMURA, D. BARATTI, G. DANIELA OLIVA, M. DERACO (<i>Milan; Messina, Italy</i>).....	187
Huge Cholesterol Granuloma of the Middle Ear Extending to Middle Cranial Fossa. C.H. JANG, Y.B. CHO (<i>Gwangju, South Korea</i>).....	191
* Reviews (pages 1, 123, 143)	

Electrochemotherapy Compared to Surgery for Treatment of Canine Mast Cell Tumours. V. KODRE, M. CEMAZAR, J. PECAR, G. SERSA, A. CÓR, N. TOZON (<i>Ljubljana, Slovenia</i>).....	55
A Mastic Gum Extract Induces Suppression of Growth of Human Colorectal Tumor Xenrafts in Immunodeficient Mice. K. DIMAS, S. HATZIANTONIOU, J.H. WYCHE, P. PANTAZIS (<i>Athens, Greece; Oklahoma City, OK, USA</i>)	63
Chondroitin Sulfate A Regulates Fibrosarcoma Cell Adhesion, Motility and Migration through JNK and Tyrosine Kinase Signaling Pathways. E. FTHENOU, F. ZONG, A. ZAFIROPOULOS, K. DOBRA, A. HJERPE, G.N. TZANAKAKIS (<i>Heraklion, Greece; Stockholm, Sweden</i>)	69
Adenovirus-mediated Thymidine Kinase Gene Therapy Induces Apoptosis in Human Epithelial Ovarian Cancer Cells and Damages PARP-1. D.G. KIEBACK (<i>Aue, Germany; Maastricht, The Netherlands</i>).....	77
Characterization of Intrinsic Efflux Activity of <i>Enterococcus faecalis</i> ATCC29212 by a Semi-automated Ethidium Bromide Method. G. SPENGLER, A. MARTINS, Z. SCHELZ, L. RODRIGUES, L. AAGAARD, M. MARTINS, S. SANTOS COSTA, I. COUTO, M. VIVEIROS, S. FANNING, J.E. KRISTIANSEN, J. MOLNAR, L. AMARAL (<i>Lisbon, Portugal; Szeged, Hungary; Sønderborg, Denmark; Dublin, Ireland;</i>).....	81
Intrafollicular Levels of Matrix Metalloproteinases-2 and -9 in Patients with Polycystic Ovaries are not Associated with Pregnancy Rate During IVF Cycle. S. BAKA, K. ZOURLA, A. MALAMITSI-PUCHNER, E. MAKRAKIS, G. KAPAROS, S. DEMERIDOU, T. MOUSTAKARIAS, D. TZANAKAKI, D. HASSIAKOS, E. KOUSKOUNI (<i>Athens, Greece</i>)	89
Jejunal Pouch Reconstruction but not Preservation of Duodenal Passage after Total Gastrectomy Reduces Plasma Cholecystokinin and Pancreatic Polypeptide Long Term in Pigs. U. SMEDH, L. HANSSON, R. EKMAN, T. ZILLING (<i>Lund; Gothenburg; Varberg, Sweden</i>).....	93
Total Gastrectomy Causes a Sustained, Long-term Elevation of Somatostatin in Plasma, Independent of the Mode of Reconstruction in Pigs. U. SMEDH, L. HANSSON, R. EKMAN, T. ZILLING (<i>Lund; Gothenburg; Varberg, Sweden</i>).....	99
<i>Clinical Studies</i>	
¹¹ C-Methionine vs. ¹⁸ F-FDG PET in Soft Tissue Sarcoma Patients Treated with Neoadjuvant Therapy: Preliminary Results. G. GHIGI, R. MICERA, A.M. MAFFIONE, P. CASTELLUCCI, S. CAMMELLI, I. AMMENDOLIA, C. NANNI, E. BARBIERI, G. GRASSETTO, S. FANTI, D. RUBELLO (<i>Bologna; Rovigo, Italy</i>).....	105
Adenomatoid Odontogenic Tumor (AOT) of Maxillary Sinus: Case Report with Respect to Immunohistochemical Findings. R.E. FRIEDRICH, H.A. SCHEUER, J. ZUSTIN (<i>Hamburg, Germany</i>).....	111
Long-term Follow-up Control of Pedunculated Orbital Floor Osteoma Becoming Symptomatic by Atypical Facial Pain. R.E. FRIEDRICH (<i>Hamburg, Germany</i>).....	117
* Fertility Preservation for Young Female Cancer Patients. T. MALTARIS, M.W. BECKMANN, R. DITTRICH (<i>Erlangen, Germany</i>)	123
Intra-arterial Hepatic Chemoembolization (TACE) of Liver Metastases from Ocular Melanoma with Slow-release Irinotecan-eluting Beads. Early Results of a Phase II Clinical Study. G. FIORENTINI, C. ALIBERTI, A. DEL CONTE, M. TILLI, S. ROSSI, P. BALLARDINI, G. TURRISI, G. BENEÀ (<i>Empoli; Ferrara, Italy</i>)	131